S100B Serum Levels Predict Treatment Response in Patients with Melancholic Depression
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There is an ongoing search for biomarkers in psychiatry, for example, as diagnostic tools or predictors of treatment response. The neurotrophic factor S100 calcium binding protein B (S100B) has been discussed as a possible predictor of antidepressant response in patients with major depression, but also as a possible biomarker of an acute depressive state. The aim of the present study was to study the association of serum S100B levels with antidepressant treatment response and depression severity in melancholically depressed inpatients. METHODS: After a wash-out period of 1 week, 40 inpatients with melancholic depression were treated with either venlafaxine or imipramine. S100B levels and Hamilton Depression Rating Scale (HAM-D) scores were assessed at baseline, after 7 weeks of treatment, and after 6 months. RESULTS: Patients with high S100B levels at baseline showed a markedly better treatment response defined as relative reduction in HAM-D scores than those with low baseline S100B levels after 7 weeks (P=.002) and 6 months (P=.003). In linear regression models, S100B was a significant predictor for treatment response at both time points. It is of interest to note that nonresponders were detected with a predictive value of 85% and a false negative rate of 7.5%. S100B levels were not associated with depression severity and did not change with clinical improvement. CONCLUSIONS: Low S100B levels predict nonresponse to venlafaxine and imipramine with high precision. Future studies have to show which treatments are effective in patients with low levels of S100B so that this biomarker will help to reduce patients' burden of nonresponding to frequently used antidepressants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848 · cited 2×
“…S100B also has an immune-modulatory function (Donato et al., 2009) and immune dysregulation has been frequently described in major depression (eg, Miller et al., 2009; Zunszain et al., 2013; Carvalho et al., 2014; Grosse et al., 2015), it would be interesting to analyze how S100B relates to…”
BackgroundBeyond diathesis stress: differential susceptibility to environmental influences
Belsky, J., & Pluess, M. (2009) · Psychological Bulletin · doi:10.1037/a0017376 · Cited by 3,039 · cited 1×
“Thus, elevated S100B expression might be associated with a differential susceptibility to environmental stimuli and could act as a plasticity factor in the way it has been proposed by Belsky and Pluess (2009).”
BackgroundRaison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617 · cited 1×
“structural neuroimaging, or gene-environment interactions in the etiology of the disorder (Fu et al., 2013; Klengel and Binder, 2013; Lim et al., 2013; Raison et al., 2013; Sämann et al., 2013; Uher et al., 2014).”
BackgroundVulnerability genes or plasticity genes?
Belsky, J., Jonassaint, C., Pluess, M., Stanton, M., Brummett, B., & Williams, R. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.44 · Cited by 1,017 · cited 1×
“Consequently, functional variants in the S100B gene would represent plasticity alleles rather than risk alleles (Belsky et al., 2009).”
BackgroundKapur, S., Phillips, A. G., & Insel, T. R. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.105 · Cited by 980 · cited 1×
“In addition, funding agencies and pharmaceutical companies increasingly request objective measures besides clinical data to invest in psychiatric research in the future (Kapur et al., 2012).”
BackgroundMiR-16 Targets the Serotonin Transporter: A New Facet for Adaptive Responses to Antidepressants
Baudry, A., Mouillet-Richard, S., Schneider, B., Launay, J.-M., & Kellermann, O. (2010) · Science · doi:10.1126/science.1193692 · Cited by 480
Fu, C. H. Y., Steiner, H., & Costafreda, S. G. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.05.008 · Cited by 399 · cited 2×
“…accounting for a slightly elevated mean level in the total group at this time point. structural neuroimaging, or gene-environment interactions in the etiology of the disorder (Fu et al., 2013; Klengel and Binder, 2013; Lim et al., 2013; Raison et al., 2013; Sämann et al., 2013; Uher et al., 2014).”
BackgroundNeuronal network plasticity and recovery from depression
Castrén, E. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1 · Cited by 190 · cited 2×
“…reduced neurotrophic factor expression, impaired neuroplastic function, and even mild forms of brain atrophy in certain brain structures in major depression, it is assumed that restoring neuroplastic function in depressive patients is a fundamental part of behavioral improvement (Castrén, 2013).”
BackgroundSerum markers support disease-specific glial pathology in major depression
Schroeter, M. L., Abdul-Khaliq, H., Krebs, M., Diefenbacher, A., & Blasig, I. E. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.03.005 · Cited by 152
Carvalho, L. A., Bergink, V, Sumaski, L., Wijkhuijs, J., Hoogendijk, W. J., Birkenhager, T. K., & Drexhage, H. A. (2014) · Translational Psychiatry · doi:10.1038/tp.2013.118 · Cited by 139
Self-citationGos, T., Schroeter, M. L., Lessel, W., Bernstein, H.-G., Dobrowolny, H., Schiltz, K., Bogerts, B., & Steiner, J. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.07.005 · Cited by 106
Prediction of antidepressant treatment response from gray matter volume across diagnostic categories
Sämann, P. G., Höhn, D., Chechko, N., Kloiber, S., Lucae, S., Ising, M., Holsboer, F., & Czisch, M. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.07.004 · Cited by 55 · cited 1×
“structural neuroimaging, or gene-environment interactions in the etiology of the disorder (Fu et al., 2013; Klengel and Binder, 2013; Lim et al., 2013; Raison et al., 2013; Sämann et al., 2013; Uher et al., 2014).”
Background
Cited by
The S100B story: from biomarker to active factor in neural injury
Michetti, F., D'Ambrosi, N., Toesca, A., Puglisi, M. A., Serrano, A., Marchese, E., Corvino, V., & Geloso, M. C. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14574 · Cited by 410
NLRP3 inflammasome-driven pathways in depression: clinical and preclinical findings
Kaufmann, F. N., Costa, A. P., Ghisleni, G., Diaz, A. P., Rodrigues, A. L. S., Peluffo, H., & Kaster, M. P. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.03.002 · Cited by 370
Molecular adaptations of the blood–brain barrier promote stress resilience vs. depression
Dudek, K. A., Dion-Albert, L., Lebel, M., LeClair, K., Labrecque, S., Tuck, E., Ferrer Perez, C., Golden, S. A., Tamminga, C., Turecki, G., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914655117 · Cited by 361
“In support of this, reduction of brain-associated markers in blood serum, an indirect indication of BBB integrity, has been shown to be predictive of antidepressant response (49).”
Thelin, E. P., Nelson, D. W., & Bellander, B.-M. (2017) · Acta Neurochirurgica · doi:10.1007/s00701-016-3046-3 · Cited by 317
Depression and sterile inflammation: essential role of danger associated molecular patterns
Franklin, T. C., Xu, C., & Duman, R. S. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.10.025 · Cited by 204
Metadata
- Authors
- Ambrée, O., Bergink, V., Grosse, L., Alferink, J., Drexhage, H. A., Rothermundt, M., Arolt, V., & Birkenhäger, T. K.
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-09-12
- Volume
- 19
- Issue
- 3
- Pages
- pyv103
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2291292537
- Cited by
- 71
- References
- 12
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.